Articles About Medtech

The “Super Vaccine” and Your 10X Profit Potential Within the Next Year

0 | By Strategic Tech Investor Staff

From scientists to business leaders, there’s one thing most people can agree on – life will not return to normal and our economy will not reach maximum production until a vaccine for COVID-19 is in hand. To find this vaccine, the convergence between tech and medicine is creating a biotechnology revolution.

Operation Warp Speed (OWS), an initiative in the United States, aims to deliver over 300 million doses of a safe, effective vaccine for COVID-19 by January 19, 2021.

And as of this writing, what we call a new, viable “Super Vaccine” is pushing to begin production of up to one billion doses. Right now, a tiny company behind the Super-Vaccine has a mere $60 million a year in sales.

But with production expected to begin imminently, it could create a staggering 58,300% revenue surge by year’s end

Wall Street Counted This Dental Tech Innovator Out – Here are Five Reasons Why You Should Buy Them Anyways

0 | By Michael A. Robinson

We’re coming up on the one-year anniversary of what at the time seemed like a controversial call.

But it turned out to be very profitable.

See, back on July 26, 2019, I suggested you invest in a breakout stock that had just gotten slaughtered.

My column appeared the very day after the company I have in mind lost more than 25% of its value – in a single session.

Despite that drubbing, I struck a very confident tone. How could I be so sure of a strong return?

Fair question. Simple answer. The company has a long track record of excellent earnings growth.

And those kinds of stocks very often not only weather setbacks but go on to become market leaders once again. This medical device leader rallied back by 40% in just five months.

Today, I want to show you five reasons why in just 10 weeks this stock had peak gains during the coronavirus comeback of 104%

One In Five Americans Could Need This Company’s Services By 2030 – And They Can Claim You A Piece Of $225 Billion

0 | By Michael A. Robinson

The easiest class I took in college more than 40 years ago is turning out to be very valuable these days.

It was a sociology course on aging that I rarely attended. But I did read the textbook carefully,

And I’m glad I did. It helped prepare for recent events involving my in-laws and my dad.

We recently had to move my aging in-laws into an assisted living facility. Meanwhile my dad, age 87, wants to remain at home but needs regular care.

I’m bringing this all up because it’s part of a huge national trend. By 2030, 20% of the population will be seniors, nearly double the figure in 2009.

By 2024, this demographic will push the home healthcare market to $225 billion, up 125% from the 2016 level.

And today, I’m going to reveal a leader in this field whose stock could double in less than two years

The Race for A COVID-19 Vaccine Is Speeding Up

0 | By Alex Kagin

July 4 is one of my favorite holidays, and living in D.C., the excitement is intensified as a huge parade marches through the city and the night concludes at the National Mall with fireworks.

But this year will be very different.

Fireworks in the nation’s capital will take place in some form with many people watching from home and the National Independence Day Parade has been cancelled. The rest of the country is also still affected by COVID-19.

Eli Lilly and Johnson & Johnson Tackle COVID-19

0 | By Alex Kagin

Living in Washington, D.C., it’s good to see that COVID-19 cases, which peaked on April 30, continue to decline. As a result, restaurants, retail stores, and some barbershops have started to open in a limited capacity.

But that reopening isn’t happening everywhere.

There are still thousands of new cases daily across the United States and many states that have started to open back up such as Texas, California, and Florida continue to see a rise in new COVID-19 cases.

Five Reasons Why This Pharmaceutical Specialist Could Double Your Money in Just Two Years

0 | By Michael A. Robinson

In our twice-weekly chats, I often suggest investments that are part of large tech sectors.

For instance, the life sciences field defines huge. Just the prescription drug segment alone will be worth $1.2 trillion by 2024, according to data from Statista.

So, you might be wondering why I am focused on a medical area that will be worth just 0.1% of that figure over roughly the same time frame.

It’s a fair question. The answer is pretty basic. A high-octane leader
focused on specialty drugs can make a killing.

And the one I’m going to reveal to you today defines profit machine. It’s on pace to double per-share earnings in as little as a year.

With that in mind, let me show you five reasons why this wealth-building biotech firm should at the very least be on your radar screen….

This Stock Crushed the Broader Market – And Now It’s Helping Exhausted Healthcare Workers

0 | By Michael A. Robinson

I want to start today’s chat with a tech-investing challenge.

How many of you can claim you have a stock in your portfolio that is up nearly 230% in just 16 months?

As impressive as that return sounds, it actually understates the strength of the stock I have in mind. It’s a medical device leader that recently received approval for a Covid-19 test.

It’s up 120 in the past two months alone…

But this is no flash in the pan. Even before that breakthrough occurred, the stock was a bona fide market crusher

From roughly the beginning of 2019 through the correction that began on February 19, the stock was ahead of the S&P 500 by an amazing 278.5%.

The firm I have in mind is leading the medical device market as part of a trend toward remote patient monitory.

With the coronavirus still fresh on everyone’s minds, the investment thesis is only getting better.

So, today I’m going to reveal why the stock could double in as little as three years and show you how to get in on the action

The High-Tech Outlook for the Coronavirus Crisis: Part 2

0 | By Michael A. Robinson

When we spoke on Tuesday, I made a bold prediction: the Covid-19 outbreak, while serious, will not be as bad as the worst-case predictions would have it.

For one, much of the country is already on lock-down, cutting off the spread of the disease. That is buying us some valuable time as researchers race to find a cure or at least a good treatment option.

And I’m happy to report there have been some exciting developments in the search for treatments and vaccines against Covid-19

Last week, I noted that most vaccine research remains rooted in 1950s technology.

Despite mapping the entire human genome back in April 2004, drug firms and scientists still rely on slowly growing viruses inside chicken eggs to create a vaccine.

This takes a lot of time – and a lot of eggs.

But the Covid-19 pandemic has them racing to find a treatment using novel and fascinating science.

With that in mind, today I want to take a closer look at some of the promising 21st Century research pushing the boundaries of this field

Five Good Reasons to Ignore a High Price Tag When Looking for Winning Tech Plays

0 | By Michael A. Robinson

My wife and I recently helped our daughter Jordan find a reliable used car.

And since Jordan only recently got her grad degree, I have to say she was pretty price sensitive.

She had roughly $9,000 to put down and wanted to limit her payments to about $100 a month, so there wasn’t a lot of wiggle room on cost. She bought, a 2009, one-owner, fully loaded Honda CRV with only 45,000 miles on it.

I’m bringing this up to you because I think our recent experience illustrates a very important point for tech investors.

When it comes to putting your money in stocks that can crush the market, don’t let high “sticker prices” warn you off of great opportunities to build lasting wealth.

Instead, you have to focus on the long-term upside. You know, it’s the old saw by Warren Buffett that price is what you pay but “value is what you get.”

And that really comes into play with a firm that is pioneering the field of robotic surgery.

At first glance, $600 a share seems steep. But this is a stock that could hit $1,800 a shares in as little as seven years.

Today, I’m going to reveal five reasons why we could see a 200% return from here

My Readers had the Chance to Crush the Market by 186% in 2019, but 2020 Looks Even Brighter

0 | By Michael A. Robinson

There’s no doubt about it. We are living in a time of astounding financial opportunities.

Last year, was a great one year for the average retail investor, continuing the epic bull market that began in March 2009. As we move into 2020, it looks like it has the potential to keep right on going.

The terrific economy that we’ve had has helped propel stocks to record highs. Unemployment remains at 50-year lows as real income adjusted for inflation is moving up for millions of Americans.

In a case like this, you’d think all you have to do from here on out is just coast on autopilot. After all, the bellwether S&P 500 was up roughly 28.9% for the year as of the close on December 31.

But, as impressive as that sounds, you could do much better in 2020.

That’s because the S&P 500’s numbers for the year are nothing compared to the gains members of my monthly tech investing newsletter, the Nova-X Report, scored in 2019.

Indeed, our three best performers for the year more than doubled the S&P.

With that in mind, today I want to reveal three stocks that made my Nova-X members tons of cash and show you how to get in on all the action